12 years of historical data (2014–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CRISPR Therapeutics AG currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.6B | $4.7B | $3.3B | $5.0B | $3.2B | $6.1B | $10.1B | $3.5B | $1.4B | $941M | $248M |
| Enterprise Value | $5.5B | $4.6B | $3.2B | $4.8B | $3.2B | $5.4B | $9.0B | $2.6B | $914M | $701M | $-67183394 |
| P/E Ratio → | -9.30 | — | — | — | — | 16.12 | — | 52.06 | — | — | — |
| P/S Ratio | 1608.41 | 1343.50 | 94.87 | 13.40 | 7248.62 | 6.67 | 14043.89 | 11.97 | 438.65 | 22.94 | 48.09 |
| P/B Ratio | 2.81 | 2.45 | 1.72 | 2.63 | 1.69 | 2.54 | 6.07 | 3.69 | 3.49 | 5.01 | 1.07 |
| P/FCF | — | — | — | — | — | 13.32 | — | 69.36 | — | — | — |
| P/OCF | — | — | — | — | — | 11.30 | — | 61.18 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1303.38 | 92.74 | 13.00 | 7322.33 | 5.91 | 12503.98 | 8.90 | 292.48 | 17.09 | -13.01 |
| EV / EBITDA | — | — | — | — | — | 13.78 | — | 50.06 | — | — | — |
| EV / EBIT | — | — | — | — | — | 14.44 | — | 55.12 | — | — | — |
| EV / FCF | — | — | — | — | — | 11.80 | — | 51.53 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
CRISPR Therapeutics AG earns an operating margin of -18933.6%. Operating margins have compressed from -60.1% to -18933.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -30.2% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -2642.3% | -2642.3% | -215.0% | 64.8% | -25186.7% | 88.9% | -37369.7% | 38.1% | -3541.9% | -70.3% | -717.9% |
| Operating Margin | -18933.6% | -18933.6% | -1333.0% | -60.1% | -154394.7% | 40.9% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% |
| Net Profit Margin | -16569.8% | -16569.8% | -1046.4% | -41.5% | -149122.7% | 41.4% | -48520.9% | 23.1% | -5281.1% | -166.7% | -449.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -30.2% | -19.2% | -8.2% | -30.4% | 18.6% | -26.8% | 10.0% | -56.9% | -32.5% | -22.8% |
| ROA | -25.8% | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% |
| ROIC | -27.4% | -27.4% | -19.5% | -9.2% | -28.0% | 24.8% | -87.8% | 72.7% | — | — | — |
| ROCE | -31.1% | -31.1% | -21.8% | -10.5% | -28.3% | 17.1% | -25.8% | 6.4% | -44.3% | -22.3% | -28.9% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $348M exceeds total debt of $207M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.09 | 0.04 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.57 | — | 1.02 | — | — | — |
| Net Debt / Equity | — | -0.07 | -0.04 | -0.08 | 0.02 | -0.29 | -0.67 | -0.95 | -1.16 | -1.28 | -1.36 |
| Net Debt / EBITDA | — | — | — | — | — | -1.78 | — | -17.32 | — | — | — |
| Debt / FCF | — | — | — | — | — | -1.53 | — | -17.83 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -8.46 |
Net cash position: cash ($348M) exceeds total debt ($207M)
Short-term solvency ratios and asset-utilisation metrics
CRISPR Therapeutics AG's current ratio of 13.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.54x to 13.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.32 | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Quick Ratio | 13.32 | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Cash Ratio | 13.25 | 13.25 | 21.69 | 15.57 | 14.99 | 19.85 | 17.93 | 16.53 | 16.46 | 16.52 | 14.34 |
| Asset Turnover | — | 0.00 | 0.02 | 0.17 | 0.00 | 0.33 | 0.00 | 0.27 | 0.01 | 0.15 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 260.71 | 197.30 | — | 0.12 | 5504.95 | 0.12 | 10.28 | 23.38 | 223.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CRISPR Therapeutics AG returns 1.3% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 6.2% | — | 1.9% | — | — | — |
| FCF Yield | — | — | — | — | — | 7.5% | — | 1.4% | — | — | — |
| Buyback Yield | 1.3% | 1.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.3% | 1.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $90M | $84M | $79M | $78M | $80M | $66M | $57M | $48M | $40M | $12M |
Compare CRSP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CRSPYou | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| PRME | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 12 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CRSP stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonCRISPR Therapeutics AG's current P/E ratio is -9.3x. The historical average is 34.1x.
CRISPR Therapeutics AG's return on equity (ROE) is -30.2%. The historical average is -19.8%.
Based on historical data, CRISPR Therapeutics AG is trading at a P/E of -9.3x. Compare with industry peers and growth rates for a complete picture.
CRISPR Therapeutics AG has -2642.3% gross margin and -18933.6% operating margin.